luvixasertib

Luvixasertib is a promising investigational anticancer agent targeting the mitotic spindle assembly checkpoint. As a highly selective TTK/Mps1 inhibitor, Luvixasertib has demonstrated potent antineoplastic activity across a broad panel of human cancer-derived cell lines. Luvixasertib works through a dual mechanism: directly inhibiting cell-cycle checkpoints in cancer cells and indirectly mobilizing immune cells from the tumor microenvironment. This dual mechanism positions Luvixasertib as a potential therapeutic for treating hepatocellular carcinoma and other solid tumors. Luvixasertib is orally bioavailable, offering the convenience of oral administration for potential cancer therapy. The compound's exceptional selectivity for TTK/Mps1 over other kinases (IC₅₀ of 1.7 nM) minimizes off-target effects, an important consideration for therapeutic development.

 

 Product Parameters

---

Parameter	Specification
Product Name	Luvixasertib
CAS Number	1610759-22-2
Molecular Formula	C28H30N6O3
Molecular Weight	498.58
Density	1.42±0.1
pKa	14.53±0.20

 

Why Cosperpharm?

---

When your oncology drug discovery program or mitotic checkpoint research requires high-quality Luvixasertib, Cosperpharm delivers with the quality, documentation, and supply reliability that researchers demand.

 

Quality that supports cutting-edge research. Our Luvixasertib is released with comprehensive analytical characterization including HPLC purity verification, NMR structural confirmation, and mass spectrometry identity verification. Every batch is accompanied by a Certificate of Analysis with full chromatographic traceability.

 

Documentation for your research needs. Each shipment includes a COA with batch-specific purity data, an SDS, and full customs documentation. For customers engaged in preclinical studies, Cosperpharm provides comprehensive documentation packages upon request.

 

Flexible supply for all research scales. Cosperpharm supplies Luvixasertib from milligram quantities for screening and kinase assays to gram-scale batches for preclinical studies.

 

Technical expertise in kinase inhibitor chemistry. Our team understands the synthetic and analytical challenges of TTK/Mps1 inhibitors and can provide technical support for your Luvixasertib-related projects.

 

Global reach with transparent pricing. Cosperpharm ships to pharmaceutical companies, CROs, and research institutions worldwide. Volume discounts apply and we communicate lead times upfront.

 

Product Advantages

---

 Highly Selective TTK/Mps1 Inhibition

Luvixasertib is a highly selective inhibitor of TTK/Mps1 with an IC₅₀ of 1.7 nM and a Ki of 0.1 nM. This exceptional selectivity minimizes off-target effects, making it an ideal tool compound for studying the spindle assembly checkpoint.

 

 Orally Bioavailable

Luvixasertib is orally bioavailable, enabling convenient oral administration in preclinical studies and potential therapeutic applications.

 

 Potent Antineoplastic Activity

Luvixasertib demonstrates strong antineoplastic activity on a broad panel of human cancer-derived cell lines, supporting its potential as a therapeutic agent across multiple cancer types.

 

 Dual Mechanism of Action

Luvixasertib works through a dual mechanism: directly inhibiting cell-cycle checkpoints in cancer cells and indirectly mobilizing immune cells from the tumor microenvironment. This dual approach may enhance anti-tumor efficacy.

 

 Potential for Hepatocellular Carcinoma

Luvixasertib has been identified as a potential therapeutic for treating hepatocellular carcinoma, addressing a significant unmet medical need in liver cancer treatment.

 

Product Quality Assurance

---

Cosperpharm has established a comprehensive quality assurance system for Luvixasertib that meets the rigorous expectations of pharmaceutical research and development:

 

Thorough analytical characterization. Each batch undergoes multi-technique analytical release testing including HPLC purity verification, NMR structural confirmation, mass spectrometry identity verification, and appearance verification.

 

Full batch traceability. From raw material procurement through synthesis, purification, and final packaging, every step is fully documented and traceable. Each batch receives a unique lot number with retention samples maintained.

 

Stability monitoring. Cosperpharm conducts ongoing stability studies under recommended storage conditions.

 

Documentation ready for regulatory submission. Every shipment includes a COA with batch-specific purity and characterization data, an SDS, and customs documentation. For customers preparing regulatory submissions, comprehensive documentation packages are available upon request.

 

Contact Us

---

Interested in Luvixasertib for your oncology drug discovery, mitotic checkpoint research, or kinase inhibitor development program? Cosperpharm is ready to supply high-purity material with the documentation and support you require. Contact us today — let's discuss how we can help advance your research.